Schering: Approvable letter for new contrast agent MS-325
MS-325 is anticipated to be the first in a new class of blood pool contrast agents for magnetic resonance angiography (MRA) to diagnose vascular disease. In the approvable letter, the FDA requested additional studies to support the application for MS-325 in enhanced MRA.
MS-325 was co-developed under a strategic partnership with EPIX and Schering has the global marketing rights for the product. Schering has also submitted MS-325 for approval in Europe.
Organizations
Other news from the department research and development
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.